A Failed Phase 3 Drug Shows Signs of Life in Follow-On Data
Fasedienol missed its Phase 3 goal in June. The open-label follow-on data looks more encouraging — but there was no placebo group to compare against.
ticker-vtgn
1 storyCoverage
Fasedienol missed its Phase 3 goal in June. The open-label follow-on data looks more encouraging — but there was no placebo group to compare against.
One email each trading morning. Free.